Please wait a minute...
Journal of Neurorestoratology  2014, Vol. 2 Issue (1): 47-64    doi: 10.2147/JN.S50114
OriginNal Rresearch     
Cerebrolysin protects against rotenone-induced oxidative stress and neurodegeneration
Omar ME Abdel-Salam1, Nadia A Mohammed2, Eman R Youness2, Yasser A Khadrawy3, Enayat A Omara4, Amany A Sleem5
1Department of Toxicology and Narcotics,;
2Department of Medical Biochemistry,;
3Department of Physiology,;
4Department of Pathology,;
5Department of Pharmacology, National Research Centre, Dokki, Cairo, Egypt
Download: PDF (18911 KB)     
Export: BibTeX | EndNote (RIS)      

Abstract  We investigated the effect of cerebrolysin, a peptide mixture used for promoting memory and recovery from cerebral stroke, on the development of oxidative stress and nigrostriatal cell injury induced by rotenone administration in rats. Rotenone 1.5 mg/kg was given subcutaneously three times weekly either alone or in combination with cerebrolysin at 21.5, 43, or 86 mg/kg. Rats were euthanized 14 days after starting the rotenone injection. Lipid peroxidation (malondialdehyde), reduced glutathione (GSH), nitric oxide (nitrite) concentrations, paraoxonase 1 (PON1), and acetylcholinesterase (AChE) activities - as well as the monocyte chemoattractant protein-1 (MCP-1) and the antiapoptotic protein Bcl-2 - were measured in the brain. Histopathology, tyrosine hydroxylase, inducible nitric oxide synthase (iNOS), tumor necrosis factor-α (TNF-α), and cleaved caspase-3 immunohistochemistry were also performed. Rotenone caused a significantly elevated oxidative stress and proinflammatory response in the different brain regions. Malondialdehyde and nitric oxide concentrations were significantly increased, while GSH markedly decreased in the cerebral cortex, striatum, hippocampus, and in the rest of the brain. PON1 and AChE activities significantly decreased with respect to the control levels after rotenone application. Striatal Bcl-2 was significantly decreased while MCP-1 increased following rotenone injection. Rotenone caused prominent iNOS, TNF-α, and caspase-3 immunostaining in the striatum and resulted in markedly decreased tyrosine hydroxylase immunoreactivity in the substantia nigra and striatum. Cerebrolysin coadministered with rotenone decreased lipid peroxidation, increased GSH, and inhibited the elevation of nitric oxide induced by rotenone. Cerebrolysin also decreased the rotenone-induced decline in the PON1 and AChE activities and the rotenone-mediated changes in the striatal Bcl-2 and MCP-1 levels. The drug reduced iNOs, TNF-α, and caspase 3 expressions and increased the tyrosine hydroxylase immunoreactivity in the striatum. Cerebrolysin markedly prevented the development of neuronal damage in the cortex and striatum. These data suggest that cerebrolysin may have potential therapeutic effect in Parkinson’s disease.

Key wordsbrain oxidative stress      neuroinflammation      apoptosis      nigrostriatal damage     
Published: 26 December 2014
Corresponding Authors: Omar ME Abdel-Salam, Department of Toxicology and Narcotics, National Research Centre, 33 Tahrir Street, Dokki, Cairo, Egypt, Tel +20 233 371 362, Fax +20 233 370 931, Email omasalam@hotmail.com   
Cite this article:

Omar ME Abdel-Salam, Nadia A Mohammed, Eman R Youness, Yasser A Khadrawy, Enayat A Omara, Amany A Sleem. Cerebrolysin protects against rotenone-induced oxidative stress and neurodegeneration. Journal of Neurorestoratology, 2014, 2: 47-64.

URL:

http://jnr.tsinghuajournals.com/10.2147/JN.S50114     OR     http://jnr.tsinghuajournals.com/Y2014/V2/I1/47

1. Benninger DH, Thees S, Kollias SS, Bassetti CL, Waldvogel D.Morphological differences in Parkinson’s disease with and without rest tremor.J Neurol. 2009;256(2):256-263.
2. Hughes AJ, Daniel SE, Kilford L, Lees AJ.Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases.J Neurol Neurosurg Psychiatry. 1992;55(3):181-184.
3. Berardelli A, Rothwell JC, Thompson PD, Hallett M.Pathophysiology of bradykinesia in Parkinson’s disease.Brain. 2001;124(Pt 11):2131-2146.
4. Santens P, Boon P, Van Roost D, Caemaert J.The pathophysiology of motor symptoms in Parkinson’s disease.Acta Neurol Belg. 2003;103(3):129-134.
5. Pankratz N, Foroud T.Genetics of Parkinson disease.Genet Med. 2007;9(12):801-811.
6. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of Parkinson’s disease: a review of the evidence. Eur J Epidemiol.2011;26 Suppl 1:S1-S58.
7. Hancock DB, Martin ER, Mayhew GM, et al.Pesticide exposure and risk of Parkinson’s disease: a family-based case-control study.BMC Neurol. 2008;8:6.
8. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson’s disease.Nat Neurosci. 2000;3(12):1301-1306.
9. Sherer TB, Kim JH, Betarbet R, Greenamyre JT.Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation.Exp Neurol. 2003;179(1):9-16.
10. Rascol O, Lozano A, Stern M, Poewe W.Milestones in Parkinson’s disease therapeutics.Mov Disord. 2011;26(6):1072-1082.
11. Mallory M, Honer W, Hsu L, Johnson R, Rockenstein E, Masliah E.In vitro synaptotrophic effects of Cerebrolysin in NT2N cells.Acta Neuropathol. 1999;97(5):437-446.
12. Hartbauer M, Hutter-Paier B, Skofitsch G, Windisch M.Antiapoptotic effects of the peptidergic drug cerebrolysin on primary cultures of embryonic chick cortical neurons.J Neural Transm. 2001;108(4):459-473.
13. Ladurner G, Kalvach P, Moessler H; Cerebrolysin Study Group.Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial.J Neural Transm. 2005;112(3):415-428.
14. Ren J, Sietsma D, Qiu S, Moessler H, Finklestein SP.Cerebrolysin enhances functional recovery following focal cerebral infarction in rats.Restor Neurol Neurosci. 2007;25(1):25-31.
15. Heiss WD, Brainin M, Bornstein NM, Tuomilehto J, Hong Z; Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial.Stroke. 2012;43(3):630-636.
16. Wong GK, Zhu XL, Poon WS.Beneficial effect of cerebrolysin on moderate and severe head injury patients: result of a cohort study.Acta Neurochir Suppl. 2005;95:59-60.
17. Ruther E, Ritter R, Apecechea M, Freitag S, Windisch M.Efficacy of Cerebrolysin in Alzheimer’s disease. In: Jellinger KA, Ladurner G, Windisch M, editors. New Trends in the Diagnosis and Therapy of Alzheimer’s Disease. Vienna: Springer-Verlag; 1994:131-141.
18. Alvarez XA, Cacabelos R, Laredo M, et al.A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer’s disease.Eur J Neurol. 2006;13(1):43-54.
19. Damulin IV, Koberskaya NN, Mkhitaryan EA.Effects of cerebrolysin on moderate cognitive impairments in cerebral vascular insufficiency (a clinical-electrophysiological study).Neurosci Behav Physiol. 2008;38(6):639-645.
20. Allegri RF, Guekht A. Cerebrolysin improves symptoms and delays progression in patients with Alzheimer’s disease and vascular dementia. Drugs Today (Barc).2012;48 Suppl A:25-41.
21. Bajenaru O, Tiu C, Moessler H, et al.Efficacy and safety of Cerebrolysin in patients with hemorrhagic stroke.J Med Life. 2010;3(2):137-143.
22. Thome J, Doppler E. Safety profile of Cerebrolysin: clinical experience from dementia and stroke trials. Drugs Today (Barc).2012;48 Suppl A:63-69.
23. Rockenstein E, Adame A, Mante M, Moessler H, Windisch M, Masliah E.The neuroprotective effects of Cerebrolysin in a transgenic model of Alzheimer’s disease are associated with improved behavioral performance.J Neural Transm. 2003;110(11):1313-1327.
24. Safarova ER, Shram SI, Grivennikov IA, Myasoedov NF.Trophic effects of nootropic peptide preparations cerebrolysin and semax on cultured rat pheochromocytoma.Bull Exp Biol Med. 2002;133(4):401-403.
25. Sharma HS, Zimmermann-Meinzingen S, Sharma A, Johanson CE.Cerebrolysin attenuates blood-brain barrier and brain pathology following whole body hyperthermia in the rat.Acta Neurochir Suppl. 2010;106:321-325.
26. Sharma HS, Zimmermann-Meinzingen S, Johanson CE.Cerebrolysin reduces blood-cerebrospinal fluid barrier permeability change, brain pathology, and functional deficits following traumatic brain injury in the rat.Ann N Y Acad Sci. 2010;1199:125-137.
27. Zhang C, Chopp M, Cui Y, et al.Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke.J Neurosci Res. 2010;88(15):3275-3281.
28. Menon PK, Muresanu DF, Sharma A, Mössler H, Sharma HS.Cerebrolysin, a mixture of neurotrophic factors induces marked neuroprotection in spinal cord injury following intoxication of engineered nanoparticles from metals.CNS Neurol Disord Drug Targets. 2012;11(1):40-49.
29. Formichi P, Radi E, Battisti C, Di Maio G, Muresanu D, Federico A.Cerebrolysin administration reduces oxidative stress-induced apoptosis in lymphocytes from healthy individuals.J Cell Mol Med. 2012;16(11):2840-2843.
30. Miller RL, James-Kracke M, Sun GY, Sun AY.Oxidative and inflammatory pathways in Parkinson’s disease.Neurochem Res. 2009;34(1):55-65.
31. Paget GE, Barnes JM.Toxicity testing. In: Laurence DR, Bacharach AL, editors. Evaluation of Drug Activities Pharmacometics. London: Academic Press; 1964:134-166.
32. Ruiz-Larrea MB, Leal AM, Liza M, Lacort M, de Groot H. Antioxidant effects of estradiol and 2-hydroxyestradiol on iron-induced lipid peroxidation of rat liver microsomes.Steroids. 1994;59(6):383-388.
33. Ellman GL.Tissue sulfhydryl groups.Arch Biochem Biophys. 1959;82(1):70-77.
34. Moshage H, Kok B, Huizenga JR, Jansen PL.Nitrite and nitrate determination in plasma: a critical evaluation.Clin Chem. 1995; 41(6 Pt 1):892-896.
35. Higashino K, Takahashi Y, Yamamura Y.Release of phenyl acetate esterase from liver microsomes by carbon tetrachloride.Clin Chim Acta. 1972;41:313-320.
36. Watson AD, Berliner JA, Hama SY, et al.Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein.J Clin Invest. 1995;96(6):2882-2891.
37. Ellman GL, Courtney KD, Andres V Jr, Feather-Stone RM.A new and rapid colorimetric determination of acetylcholinesterase activity.Biochem Pharmacol. 1961;7:88-95.
38. Gorun V, Proinov I, Baltescu V, Balaban G, Barzu O.Modified Ellman procedure for assay of cholinesterases in crude enzymatic preparations.Anal Biochem. 1978;86(1):324-326.
39. Feng Y, Liang ZH, Wang T, Qiao X, Liu HJ, Sun SG. alpha-Synuclein redistributed and aggregated in rotenone-induced Parkinson’s disease rats.Neurosci Bull. 2006;22(5):288-293.
40. Sherer TB, Betarbet R, Testa CM, et al.Mechanism of toxicity in rotenone models of Parkinson’s disease.J Neurosci. 2003;23(34):10756-10764.
41. Testa CM, Sherer TB, Greenamyre JT.Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures.Brain Res Mol Brain Res. 2005;134(1):109-118.
42. Meister A.Glutathione metabolism and its selective modification.J Biol Chem. 1988;263(33):17205-17208.
43. Cotgreave IA, Gerdes RG.Recent trends in glutathione biochemistry - glutathione-protein interactions: a molecular link between oxidative stress and cell proliferation?Biochem Biophys Res Commun. 1998;242(1):1-9.
44. Dringen R.Metabolism and functions of glutathione in brain.Prog Neurobiol. 2000;62(6):649-671.
45. Bains JS, Shaw CA.Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death.Brain Res Brain Res Rev. 1997;25(3):335-358.
46. Kaur D, Lee D, Ragapolan S, Andersen JK.Glutathione depletion in immortalized midbrain-derived dopaminergic neurons results in increases in the labile iron pool: implications for Parkinson’s disease.Free Radic Biol Med. 2009;46(5):593-598.
47. Jha N, Jurma O, Lalli G, et al.Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity. Implications for Parkinson’s disease.J Biol Chem. 2000;275(34):26096-26101.
48. Schulz JB, Lindenau J, Seyfried J, Dichgans J.Glutathione, oxidative stress and neurodegeneration.Eur J Biochem. 2000;267(16):4904-4911.
49. Dean OM, van den Buuse M, Bush AI, et al. A role for glutathione in the pathophysiology of bipolar disorder and schizophrenia? Animal models and relevance to clinical practice.Curr Med Chem. 2009;16(23):2965-2976.
50. Gawryluk JW, Wang JF, Andreazza AC, Shao L, Young LT.Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders.Int J Neuropsychopharmacol. 2011;14(1):123-130.
51. Sofic E, Lange KW, Jellinger K, Riederer P.Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson’s disease.Neurosci Lett. 1992;142(2):128-130.
52. Sian J, Dexter DT, Lees AJ, et al.Alterations in glutathione levels in Parkinson’s disease and other neurodegenerative disorders affecting basal ganglia.Ann Neurol. 1994;36(3):348-355.
53. Fitzmaurice PS, Ang L, Guttman M, Rajput AH, Furukawa Y, Kish SJ.Nigral glutathione deficiency is not specific for idiopathic Parkinson’s disease.Mov Disord. 2003;18(9):969-976.
54. Sechi G, Deledda MG, Bua G, et al.Reduced intravenous glutathione in the treatment of early Parkinson’s disease.Prog Neuropsychopharmacol Biol Psychiatry. 1996;20(7):1159-1170.
55. Wei T, Chen C, Hou J, Xin W, Mori A.Nitric oxide induces oxidative stress and apoptosis in neuronal cells.Biochim Biophys Acta. 2000; 1498(1):72-79.
56. Bal-Price A, Brown GC.Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity.J Neurosci. 2001;21(17):6480-6491.
57. Förstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J.2012;33(7):829-837, 837a-837d.
58. Kovac A, Erickson MA, Banks WA.Brain microvascular pericytes are immunoactive in culture: cytokine, chemokine, nitric oxide, and LRP-1 expression in response to lipopolysaccharide.J Neuroinflammation. 2011;8:139.
59. Abdel-Salam OME, Omara EA, El-Shamarka MES, Hussein JS.Nigrostriatal damage after systemic rotenone and/or lipopolysaccharide and the effect of cannabis.Comparative Clinical Pathology. 2013;1-16.
60. Bashkatova V, Alam M, Vanin A, Schmidt WJ.Chronic administration of rotenone increases levels of nitric oxide and lipid peroxidation products in rat brain.Exp Neurol. 2004;186(2):235-241.
61. Schmidt WJ, Alam M.Controversies on new animal models of Parkinson’s disease pro and con: the rotenone model of Parkinson’s disease (PD).J Neural Transm Suppl. 2006;(70):273-276.
62. Moncada S, Palmer RM, Higgs EA.Nitric oxide: physiology, pathophysiology, and pharmacology.Pharmacol Rev. 1991;43(2):109-142.
63. Wink DA, Mitchell JB.Chemical biology of nitric oxide: Insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide.Free Radic Biol Med. 1998;25(4-5):434-456.
64. Korhonen R, Lahti A, Kankaanranta H, Moilanen E.Nitric oxide production and signaling in inflammation.Curr Drug Targets Inflamm Allergy. 2005;4(4):471-479.
65. Mander P, Borutaite V, Moncada S, Brown GC.Nitric oxide from inflammatory-activated glia synergizes with hypoxia to induce neuronal death.J Neurosci Res. 2005;79(1-2):208-215.
66. He Y, Imam SZ, Dong Z, et al.Role of nitric oxide in rotenone-induced nigro-striatal injury.J Neurochem. 2003;86(6):1338-1345.
67. Abdel-Salam OME, Khadrawy YA, Youness ER, et al.Effect of a single intrastriatal rotenone injection on oxidative stress and neurodegeneration in the rat brain.Comparative Clinical Pathology. 2013;1-11.
68. La Du BN.Human serum paraoxonase: arylesterase. In: Kalow W, editor. Pharmacogenetics of Drug Metabolism. New York: Pergamon Press; 1992:51-91.
69. Draganov DI, La Du BN.Pharmacogenetics of paraoxonases: a brief review.Naunyn Schmiedebergs Arch Pharmacol. 2004;369(1):78-88.
70. Furlong CE.Paraoxonases: An Historical Perspective. In: Mackness B, Mackness M, Aviram M, Paragh G, editors. The Paraoxonases: Their Role in Disease Development and Xenobiotic Metabolism. Dordrecht: Springer; 2008:3-31.
71. Kondo I, Yamamoto M.Genetic polymorphism of paraoxonase 1 (PON1) and susceptibility to Parkinson’s disease.Brain Res. 1998;806(2):271-273.
72. Carmine A, Buervenich S, Sydow O, Anvret M, Olson L.Further evidence for an association of the paraoxonase 1 (PON1) Met-54 allele with Parkinson’s disease.Mov Disord. 2002;17(4):764-766.
73. Belin AC, Ran C, Anvret A, et al.Association of a protective paraoxonase 1 (PON1) polymorphism in Parkinson’s disease.Neurosci Lett. 2012;522(1):30-35.
74. Lee PC, Rhodes SL, Sinsheimer JS, Bronstein J, Ritz B.Functional paraoxonase 1 variants modify the risk of Parkinson’s disease due to organophosphate exposure.Environ Int. 2013;56:42-47.
75. Wehr H, Bednarska-Makaruk M, Graban A, et al.Paraoxonase activity and dementia.J Neurol Sci. 2009;283(1-2):107-108.
76. Zengi O, Karakas A, Ergun U, Senes M, Inan L, Yucel D.Urinary 8-hydroxy-2′-deoxyguanosine level and plasma paraoxonase 1 activity with Alzheimer’s disease.Clin Chem Lab Med. 2011;50(3):529-534.
77. Jamroz-Wisniewska A, Beltowski J, Stelmasiak Z, Bartosik-Psujek H.Paraoxonase 1 activity in different types of multiple sclerosis.Mult Scler. 2009;15(3):399-402.
78. Nguyen SD, Hung ND, Cheon-Ho P, Ree KM, Dai-Eun S.Oxidative inactivation of lactonase activity of purified human paraoxonase 1 (PON1).Biochim Biophys Acta. 2009;1790(3):155-160.
79. Thornberry NA, Lazebnik Y.Caspases: enemies within.Science. 1998;281(5381):1312-1316.
80. Budihardjo I, Oliver H, Lutter M, Luo X, Wang X.Biochemical pathways of caspase activation during apoptosis.Annu Rev Cell Dev Biol. 1999;15:269-290.
81. Yuan J, Yankner BA.Apoptosis in the nervous system.Nature. 2000;407(6805):802-809.
82. Wang X, Qin ZH, Leng Y, et al.Prostaglandin A1 inhibits rotenone-induced apoptosis in SH-SY5Y cells.J Neurochem. 2002;83(5):1094-1102.
83. Ahmadi FA, Linseman DA, Grammatopoulos TN, et al.The pesticide rotenone induces caspase-3-mediated apoptosis in ventral mesencephalic dopaminergic neurons.J Neurochem. 2003;87(4):914-921.
84. Hartmann A, Hunot S, Michel PP, et al.Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson’s disease.Proc Natl Acad Sci U S A. 2000;97(6):2875-2880.
85. Tatton NA.Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson’s disease.Exp Neurol. 2000;166(1):29-43.
86. Shimizu S, Narita M, Tsujimoto Y.Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC.Nature. 1999;399(6735):483-487.
87. Zhai D, Jin C, Huang Z, Satterthwait AC, Reed JC.Differential regulation of Bax and Bak by anti-apoptotic Bcl-2 family proteins Bcl-B and Mcl-1.J Biol Chem. 2008;283(15):9580-9586.
88. Susnow N, Zeng L, Margineantu D, Hockenbery DM.Bcl-2 family proteins as regulators of oxidative stress.Semin Cancer Biol. 2009;19(1):42-49.
89. Hochman A, Sternin H, Gorodin S, et al.Enhanced oxidative stress and altered antioxidants in brains of Bcl-2-deficient mice.J Neurochem. 1998;71(2):741-748.
90. Amstad PA, Liu H, Ichimiya M, et al.BCL-2 is involved in preventing oxidant-induced cell death and in decreasing oxygen radical production.Redox Rep. 2001;6(6):351-362.
91. Longoni B, Boschi E, Demontis GC, Marchiafava PL, Mosca F.Regulation of Bcl-2 protein expression during oxidative stress in neuronal and in endothelial cells.Biochem Biophys Res Commun. 1999;260(2):522-526.
92. Mennicken F, Maki R, de Souza EB, Quirion R. Chemokines and chemokine receptors in the CNS: a possible role in neuroinflammation and patterning.Trends Pharmacol Sci. 1999;20(2):73-78.
93. Sozzani S, Locati M, Zhou D, et al.Receptors, signal transduction, and spectrum of action of monocyte chemotactic protein-1 and related chemokines.J Leukoc Biol. 1995;57(5):788-794.
94. Orlikowski D, Chazaud B, Plonquet A, et al.Monocyte chemoattractant protein 1 and chemokine receptor CCR2 productions in Guillain-Barré syndrome and experimental autoimmune neuritis.J Neuroimmunol. 2003;134(1-2):118-127.
95. Thompson WL, Karpus WJ, Van Eldik LJ.MCP-1-deficient mice show reduced neuroinflammatory responses and increased peripheral inflammatory responses to peripheral endotoxin insult.J Neuroinflammation. 2008;5:35.
96. Yang G, Meng Y, Li W, et al.Neuronal MCP-1 mediates microglia recruitment and neurodegeneration induced by the mild impairment of oxidative metabolism.Brain Pathol. 2011;21(3):279-297.
97. Everitt BJ, Robbins TW.Central cholinergic systems and cognition.Annu Rev Psychol. 1997;48:649-684.
98. Aosaki T, Miura M, Suzuki T, Nishimura K, Masuda M. Acetylcholine-dopamine balance hypothesis in the striatum: an update. Geriatr Gerontol Int.2010;10 Suppl 1:S148-S157.
99. Fox SH.Non-dopaminergic treatments for motor control in Parkinson’s disease.Drugs. 2013;73(13):1405-1415.
100. Ullrich C, Humpel C.Rotenone induces cell death of cholinergic neurons in an organotypic co-culture brain slice model.Neurochem Res. 2009;34(12):2147-2153.
101. McCoy MK, Tansey MG. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease.J Neuroinflammation. 2008;5:45.
102. Mogi M, Togari A, Tanaka K, Ogawa N, Ichinose H, Nagatsu T.Increase in level of tumor necrosis factor (TNF)-alpha in 6-hydroxydopamine-lesioned striatum in rats without influence of systemic L-DOPA on the TNF-alpha induction.Neurosci Lett. 1999;268(2):101-104.
103. Sriram K, Matheson JM, Benkovic SA, Miller DB, Luster MI, O’Callaghan JP. Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson’s disease.FASEB J. 2002;16(11):1474-1476.
104. De Lella Ezcurra AL, Chertoff M, Ferrari C, Graciarena M, Pitossi F. Chronic expression of low levels of tumor necrosis factor-alpha in the substantia nigra elicits progressive neurodegeneration, delayed motor symptoms and microglia/macrophage activation.Neurobiol Dis. 2010;37(3):630-640.
[1] Wen-Chao Liu, Liang Wen, Hao Wang, Jiang-Biao Gong, Tian-Xiang Zhan, Yuan-Yuan Meng, Xiao-Feng Yang. Neuroprotection of hyperbaric oxygen treatment for traumatic brain injury involving autophagy pathway in rats[J]. Journal of Neurorestoratology, 2017, 5(1): 85-91.
[2] Yun-liang Wang, Jin-feng Li, Yu-tong Wang, Chun-yang Xu, Lin-lin Hua, Xiao-peng Yang, Shuang Geng, Shan-shan Wang, Zhen Wang, Hong-lei Yin. Curcumin reduces hippocampal neuron apoptosis and JNK-3 phosphorylation in rats with Aβ-induced Alzheimer’s disease: protecting spatial learning and memory[J]. Journal of Neurorestoratology, 2017, 5(1): 117-123.